Outpatient management of anticoagulation therapy

American Family Physician

Volumn 75, Issue 7, 2007, Pages 1031-1042

  Du Breuil, Anne L ^a,b   Umland, Elena M ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACOVA; AMIODARONE; ARGATROBAN; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; COLESTYRAMINE; COTRIMOXAZOLE; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; GINKGO BILOBA EXTRACT; GRISEOFULVIN; HEPARIN; HIRULOG; IPRAVASK; LEPIRUDIN; LEVOTHYROXINE; LOW MOLECULAR WEIGHT HEPARIN; METRONIDAZOLE; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTAMINE; RIFAMPICIN; SALICYLIC ACID; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

BLEEDING; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; OSTEOPENIA; OUTPATIENT CARE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

AMBULATORY CARE; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; PULMONARY EMBOLISM; RISK; VENOUS THROMBOSIS; WARFARIN;

EID: 34147119658     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [Published correction appears in Chest 2005;127:415-6]. Chest 2004;126(3 suppl):204S-33S.
2. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [Published correction appears in Chest 2005;127:416]. Chest 2004;126(3 suppl):401S-28S.
3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):338S-400S.
4. Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):179S-87S.
5. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):513S-48S.
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):188S-203S.
7. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):457S-82S.
8. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):429S-56S.
9. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):265S-86S.
10. Warfarin food interactions. Pharmacist's Letter/Prescriber's Letter 2005;21(5):210507.
11. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999;159:46-8.
12. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism: a randomized, double-blind, controlled trial. Ann Intern Med 2003;138:714-9.
13. Crowther MA, Harrison L, Hirsh J. Randomized trial of warfarin nomograms. Ann Intern Med 2004;140:490.
14. Ebell MH. Evidence-based initiation of warfarin (Coumadin). Am Fam Physician 2005;71:763-5. Available at: http://www.aafp.org/afp/20050215/poc. html.
15. Ebell MH. Evidence-based adjustment of warfarin (Coumadin) doses. Am Fam Physician 2005;71:1979-82. Available at: http://www.aafp.org/afp/20050515/poc. html.
16. Micromedex Healthcare Series 1974-2006. Thomson Healthcare Inc. Thomas Jefferson University Hospital, Philadelphia, Pa. Subscription required. Accessed October 18, 2006, at: http://www-thomsonhccom.proxy1.lib.tju.edu:2048/hcs/ librarian/.
17. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8.
18. Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med 2000;160:1769-73.
19. Trujillo-Santos J, Perea-Milla E, Jimenez-Puente A, Sanchez-Cantalejo E, del Toro J, Grau E, et al., for the RIETE Investigators. Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE registry. Chest 2005;127:1631-6.
20. Kolbach DN, Sandbrink MW, Hamulyak K, Neumann HA, Prins MH. Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 2004;(1):CD004174.
21. Lee AY. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon 2005;51:150-7.
22. Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J 2004;147:3-15.
23. Dunn A. Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis 2006;21:85-9.
24. Spandorfer J. The management of anticoagulation before and after procedures. Med Clin North Am 2001;85:1109-16.
25. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003;163:901-8.
26. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-26.
27. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004;125:1642-50.
28. Andersen JC. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Semin Thromb Hemost 2004;30:609-18.